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ABSTRACT
Objective. To assess, quantify and sum-
marise the cost of illness of rheumatoid 
arthritis (RA) and ankylosing spondyli-
tis (AS) from the societal perspective.
Methods. Original studies reporting 
costs of RA or AS were searched system-
atically. Both cost-of-illness studies and 
economic evaluations of therapies were 
included. Studies were appraised for 
patient and study characteristics, type 
of costs and actual costs. Reported costs 
were aggregated by cost categories and 
overall mean costs were summarised by 
cost domain (healthcare, patient and 
family, and productivity costs).
Results. Overall mean costs of RA 
(€14,906 per year) were above that of 
AS (€9,374 per year), while the rela-
tive distribution of costs over cost do-
mains was approximately similar. For 
both diseases, productivity costs based 
on the human cost approach were 3 to 
10 times higher than the friction costs 
and accounted for more than half the 
total costs of both diseases. 
Conclusion. Productivity costs consti-
tute the largest part of the total cost-
off-illness of RA and AS reflecting the 
high burden of the disease on work 
participation. Although total and direct 
costs of illness in RA were higher than 
in AS, the average age of AS patients 
was 10 years lower and therefore, life-
time costs associated with AS may ac-
tually be equal or higher. 
Introduction
Rheumatoid arthritis (RA) and anky-
losing spondylitis (AS) are chronic 
inflammatory rheumatic diseases char-
acterised by pain, stiffness and func-
tional limitations. These impairments 
are associated with various socio-eco-
nomic consequences for patients, their 
environment and society, such as an 
increased healthcare utilisation, a need 
for formal and informal care, and a 
reduced productivity or ability to work 
among patients (1-8). Recently, new 
drug compounds such as agents against 
tumor necrosis factor antagonists (TNF 
inhibitors) have been introduced with a 
strong effect on the inflammation in RA 
and AS and a clear potential to arrest 
radiographic damage in RA. However, 
their use is constrained by high medi-
cation costs, being €9,000–18,000 per 
year per patient (9). The challenging 
question is whether the costs of these 
drugs can be offset, at least partially, by 
savings in the costs-of-illness.
The present study aimed to provide an 
overview of the economic consequences 
of RA and AS, based on evidence from 
literature, and the relative contribution 
of different cost categories to the to-
tal disease costs. This review obtained 
cost data from bottom up cost-of-illness 
(COI) studies (i.e. based on individual 
patient data) and intervention studies, 
such as cost-effectiveness analysis or 
cost-utility analysis. This resulted in 
the following research questions: What 
type of economic consequences, related 
to RA and/or AS are reported in COI 
studies or intervention studies? What 
are the costs related to RA and/or AS 
and the variation in costs reported in 
COI studies or intervention studies?
Methodology
The search strategy
Abstracts were retrieved from the da-
tabases Medline, Embase and Econlit 
(EBSCO) through a meta-search in 
July 2007 using the terms ‘Rheumatoid 
arthritis’ or ‘Ankylosing spondylitis’ 
in combination with ‘cost-of-illness’, 
‘cost effectiveness’, ‘cost utility’ or 
‘cost analysis’ in the title, abstract or 
key words. Papers without abstracts, 
non-English papers and abstracts from 
conference papers were excluded. 
Two of the authors used the abstracts 
to independently assess the papers’ 
potential relevance to this review. All 
authors were involved in this review 
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process. Reasons to exclude abstracts 
were: 1) no information on RA or AS; 
2) no costs reported in abstract; 3) no 
primary data reported (literature re-
views for example).
Full transcripts were obtained of all ab-
stracts considered potentially relevant to 
this study by one or both reviewers. Sub-
sequently, one reviewer (LF) assessed 
the full papers. In case of uncertainty, 
the opinion of a second reviewer was 
solicited. Exclusion criteria for full pa-
pers were: 1) no primary data reported.; 
2) no costs quoted in the results section, 
no breakdown of costs, or incremental 
costs of interventions only;  3) health 
system distinct (non-western countries) 
or patient population unrepresentative 
(<30 patients); (4) Top-down approach 
adopted in COI study (for instance, 
costs based on health insurance statistics 
and not on individual patient data). The 
reference lists of retrieved papers were 
checked for other relevant studies.
Data handling
Study and patient population charac-
teristics, type of costs, cost rates, and 
mean costs were obtained using a data 
extraction form. Costs were categorised 
using a cost matrix for RA developed 
by Merkesdal et al. (10) as a basis. 
Main cost domains distinguished in the 
current extraction form were: health-
care costs, patient and family costs, and 
productivity costs. Two methods were 
used to assess productivity costs: the 
human capital approach (HCA) and the 
friction cost approach (FCA) (11, 12). 
As differences between the methods 
in costs of short-term absence or sick 
leave tend to be small, we aggregated 
short-term productivity costs. Substan-
tial differences can be found in produc-
tivity costs of long-term sickness, dis-
ability to work, and early retirement, 
and these costs were presented sepa-
rately for the two approaches. 
Extracted costs were annualised and 
converted to 2006 EU € using the 
Consumer Price Indices of the rel-
evant countries and the 2006 Pur-
chasing Power Parities between these 
countries and the EU average (13). 
Mean costs in tables represented the 
mean of costs  reported by the various 
studies. Interquartile ranges (IQR) of 
costs, i.e. the 25th and 75th percentile, 
were also presented. For studies based 
on RCTs, weighted average costs of 
the treatments were used, based on 
the number of patients per treatment. 
These weighted costs from RCTs were 




Six hundred and three (603) titles with 
abstracts on RA or AS were obtained 
through the meta-search. 89 studies on 
RA and 11 on AS fulfilled the abstract 
inclusion criteria. The assessment of 
full transcripts resulted in 25 papers on 
RA and 7 on AS considered suitable for 
this review. One paper (14) contained 
cost data on both RA and AS. Inspect-
ing the reference lists of papers resulted 
in one additional study on RA (15). An-
other paper on RA (16) was retrieved 
as it provided additional background 
data on a study (17) already retrieved. 
Hence, in total, 26 independent studies 
presenting original cost data on RA (14, 
15, 17-40), and 7 studies on AS (14, 23, 
41-45) were included. 
Study characteristics
Most published studies on RA and AS 
in this review were COI studies (Ta-
ble I). Only seven studies on RA (17, 
22, 26, 28, 33-35) and one on AS (41) 
were conducted within a RCT setting. 
These were all cost-effectiveness stud-
ies, occasionally along with a cost-util-
ity study. Four studies on RA (19, 26, 
30, 46), but no studies on AS, report-
ed costs of TNF inhibitors for disease 
treatment. Most studies considered dis-
ease-related costs only and excluded 
other healthcare expenditures (15, 17, 
21, 22, 25, 31, 32, 37, 38). Given the 
large number of co-morbidities associ-
ated with RA and AS, and the difficulty 
to attribute healthcare expenditures to a 
Table I. Characteristics of published studies on the economic consequences of rheumatoid 
arthritis and ankylosing spondylitis.
 RA                                    AS
Total number of published studies 26 7
Cost-of-illness studies 19 6
With costs of TNF-inhibitors 3 0
No costs of TNF-inhibitors 16 6
Cost-effectiveness studies 7 1
With costs of TNF-inhibitors 1 0
No costs of TNF-inhibitors 6 1
Disease-related or all healthcare costs  
Disease-related costs 16 6
All healthcare costs 10 1
Patient characteristics  
All patients 19 6
Working population 3 1
Patients with early disease (< 3 years) 4 0
Size of patient population (p)  
30   < p ≤ 200 9 1
200 < p ≤ 1000 12 5
1000 < p ≤ 8000 5 1
Geographical region  
Northern America 9 2
Netherlands 6 1
Germany 4 1
Other EU countries 7 3
Year of publication  
1988 – 1997 2 0
1998 – 2002 6 1
2003 – April 2007 18 6
Time horizon (t)  
t  ≤ 6 months 9 1
6 months < t  ≤ 1 year 10 3
1 year      < t  ≤ 3 years 7 3
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particular disease, few studies preferred 
to combine all healthcare expenditures 
incurred by RA or AS patients (19, 27, 
30, 39, 47), or presented both types of 
expenditures (24, 40). In the latter case, 
we only used disease-related costs for 
analyses as this was the most common 
approach. Most studies included RA or 
AS patients of all ages over 18 years. 
The presence of severe co-morbidities 
or pregnancy was often applied as an 
exclusion criterion. Some studies on 
RA included patients of working age 
only (<65 years) (25, 28, 29) or patients 
with early RA only (17, 21, 29, 31). 
The number of patients on which cost 
assessments were based greatly varied 
between studies. Two studies on RA 
(11, 14) included 4351 and 7527 pa-
tients. Many studies were conducted in 
the Netherlands (15, 22, 34, 35, 37, 47), 
Germany (14, 28, 29, 32), the U.S.A. 
(38, 40, 48), Canada (11, 18, 26, 27), 
and fewer in other EU countries (17, 
20, 21, 23-25, 39), including Sweden, 
Belgium, France, Spain and Italy. The 
number of cost studies of RA has rap-
idly increased in recent years. All stud-
ies in this review on AS were published 
in 2000 or later. The studies’ time ho-
rizons (i.e. the time over which costs 
of RA or AS incurred by patients was 
measured) varied between 3 months 
and 3 years. The average age of patients 
with RA was 57 years, while that of AS 
patients was 47 years. On average, 76% 
of RA patients was female, while 69% 
was male among AS patients.
Costs 
Healthcare expenditures of RA were 
greater than patient and family costs 
(Table II). Inter-quartile ranges sug-
gested that variation between studies 
in healthcare costs was less than in pa-
tient & family costs. Within healthcare 
costs, outpatient costs exceeded inpa-
tient costs. An important component of 
outpatient costs were medication costs. 
The breakdown of medication costs 
highlighted the contribution of TNF 
inhibitors to the total medication costs. 
Mean costs of TNF inhibitors, reported 
by four studies (19, 26, 30, 46), were 
more than double the overall mean ex-
penditure on medication. Inpatient costs 
were primarily driven by expenditures 
on acute hospital facilities. Non-acute 
hospital facilities represented minor 
costs, as only few patients made use of 
such facilities. Within patient & fam-
ily costs, large costs were reported for 
patient time, informal care by friends 
and family and home care services. 
However, the size of these costs greatly 
depends on the method and cost rates 
used to estimate the costs. For instance, 
the value of time varies a lot between 
studies. Moreover, the cost estimation 
of patient time was based on one study 
only. These factors contributed to the 
wide IQR of patient and family costs of 
RA, relative to the IQR of total health-
care costs
Healthcare and patient and family costs 
reported in studies of AS were also 
substantial (Table II), albeit slightly 
below those of RA. Main outpatient 
healthcare expenditures constituted 
of medication costs, visits to physi-
cians and non-physician service utili-
sation. Prescriptions of NSAIDs and 
DMARDs were major contributors 
to the total medication costs. None of 
the studies on AS assessed the costs of 
TNF inhibitors. These medicines could 
strongly increase the medication and to-
tal healthcare costs of AS if prescribed 
more frequently in the future. Within 
inpatient costs, expenditures on acute 
hospital facilities were greater than 
Table II. Mean healthcare and patient & family costs of rheumatoid arthritis and ankylos-
ing spondylitis, the associated inter-quartile range (IQR), and the number of studies (n) on 
which the costs were based (€ per patient per year).
 Rheumatoid arthritis Ankylosing spondylitis
 
 n Mean 0.25 – 0.75 IQR n Mean 0.25-0.75 IQR
Healthcare costs 23 4170 2756-4561 6 1992 1359-2474
Outpatient costs 23 2981 1754-3660 6 1400 1114-1419
Visits to physician 22 527 288-718 6 301 236-306
General Practitioner 6 105 53-158 2 38 38-39
Rheumatologist 6 314 158-425 2 158 125-192
Other specialist physician 8 153 46-234 2 156 125-188
Non-physician service utilisation 15 402 106-560 5 428 197-513
Physiotherapist 6 365 165-584 3 307 225-442
Other therapist 4 265 81-411 3 43 34-52
Clinical nurse specialist 3 204 50-283 0  
Social worker / psychologist 2 132 80-184 0  
Emergency room visit 7 133 42-194 1 0 
Medication 23 1567 605-1652 6 628 296-701
NSAIDs 6 287 94-499 1 518 
Steroids 5 48 13-70 0  
DMARDs 7 694 267-953 2 661 367-954
TNF inhibitors 4 3820 2602-4408 0  
Gastro-protection 3 224 85-299 1 87 
Analgesics 4 67 22-87 1 93 
Osteoporosis drugs 1 38  0  
Other medicines 2 253 209-296 1 344 
Diagnostic procedures 18 370 177-474 3 164 128-219
Radiographs 6 256 131-300 2 81 68-95
Other procedures 7 206 37-253 1 92 
Outpatient surgery 13 114 36-139 4 48 18-76
Inpatients costs 22 1243 446-1649 6 592 245-983
Acute hospital facilities 16 1236 431-1519 2 499 372-627
Surgery 6 256 162-239 0  
Non-surgery 5 279 237-404 0  
Non-acute hospital facilities 9 171 58-322 2 204 121-286
       
Patient and family costs 19 2284 628-3092 6 1104 541-1431
Transportation 8 70 28-102 2 54 38-71
Home care services 13 730 98-984 5 564 257-849
Home remodelling 1 288  0  
Devices and aids 14 446 65-297 3 230 37-332
Non-medical practitioner 7 131 38-220 5 400 32-798
Patient time 1 1614  1 612 
Informal care by friends and family 9 1969 450-2471 1 273 
Other costs 9 907 480-937 1 187
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costs of non-acute hospital facilities. 
Within patient and  family costs, large 
costs were recorded for home care serv-
ices, alternative therapies, and devices 
and aids. While patient time also repre-
sented high costs, these were measured 
by one study only.
Work disability/early retirement costs 
and total productivity costs calculated 
with the HCA were 3 to 10 times higher 
than the friction costs (Table III), which 
is in line with results from literature (12). 
Most studies on RA used the HCA only 
to assess total productivity costs (11, 
14, 17, 18, 20, 21, 24, 25, 28, 29, 31-33, 
46, 47). Three studies also evaluated 
the friction costs (11, 14, 47), while one 
study presented friction costs only (28). 
The distribution of costs of short-term 
absence/sick leave of RA was skewed 
due to one study presenting very high 
annual costs of short-term absence/sick 
leave (€8,452 patient-1 y-1) (29). This 
study assessed productivity costs of 
patients with early RA, which usually 
have high costs for short-term absence 
and low costs for work disability/early 
retirement. Excluding this study gave a 
mean cost for short-term absence/sick 
leave of €1,352 patient-1 y-1. A large 
variability was also observed in total 
productivity costs. An upper value was 
retrieved from a Swedish study estimat-
ing the total productivity costs of RA at 
€23,690 patient-1 y-1 (21). A study from 
Spain presented total productivity costs 
of €629 patient-1 y-1 (24). Both stud-
ies used the HCA and this difference 
was primarily the result of variation in 
assumed wages to value time absent 
from work. Five studies on AS assessed 
the overall productivity costs using the 
HCA (14, 23, 42, 44, 45). One study ap-
plied both the HCA and the FCA (14), 
while another study used the FCA only 
(41). Total productivity costs of AS 
were slightly below those of RA. 
Mean total cost (the sum of the total 
healthcare, patient and family and pro-
ductivity costs (HCA) in Tables II & 
III) was €14,906 per patient per year 
for RA and €9,374 per patient per year 
for AS. Productivity costs (HCA) ac-
counted for 57% of the total costs of 
RA and for 66% of the total costs of AS. 
This large share of productivity costs in 
the total costs reflected the high burden 
of both diseases on work participation.
Discussion
While annual societal costs per patient 
were higher for RA for almost all cost 
categories than for AS, the average age 
of onset of AS is about 15 years earlier 
than of RA patients, suggesting the life-
time costs of AS may well be equal or 
higher than that of RA. As yet, no study 
has looked at this issue. Notwithstand-
ing, this is relevant when assessing the 
long-term costs-effectiveness of inter-
ventions. Medication costs were the 
major contributors to the total health-
care costs of RA and AS. Productivity 
costs had a very large share in the total 
costs of both diseases, but varied on the 
methodology and cost rates applied. 
This review has clear limitations. Stud-
ies fulfilling the inclusion criteria were 
not rated on methodological qualities, 
and consequently studies with different 
methodological designs were treated 
equally. This approach was chosen 
given the difficulty to define objec-
tive criteria for rating methodological 
qualities of cost studies. In addition, 
the large number of studies available 
on RA (26) implied that describing 
each study in sufficient detail to ex-
plain variation in costs between stud-
ies would go beyond the study’s scope. 
Notwithstanding, when different cost-
ing methodologies had a large impact 
on the cost estimates (e.g. different 
approaches used to assess productiv-
ity costs), this was highlighted. Fewer 
studies on costs of AS were retrieved. 
Here, a more narrative approach and a 
more detailed assessment of the differ-
ences in costs would have been feasible 
(51). Our approach was supported by 
the fairly narrow inter-quartile ranges 
of mean costs, especially of healthcare 
costs, suggesting that mean costs of RA 
and AS among large groups of patients 
was reasonably stable, irrespective of 
the methodology followed to collect or 
present data. The variation in costs be-
tween patients within studies was often 
larger.
The expected rise in the use of TNF in-
hibitors for RA and AS treatment in the 
near future is likely to result in a strong 
increase in medication costs as already 
shown by several studies (9, 50, 51). On 
the long term, however, treatment with 
TNF inhibitors will reduce functional 
disabilities caused by RA or AS, which 
in turn can result in reduced productiv-
ity costs. However, the link between 
better treatment effects and reduction 
of the long-term productivity costs has 
not been well established. Therefore, 
future research on the economic con-
sequences of RA and AS should focus 
on assessing the long-term productiv-
ity costs of the diseases, particularly in 
relation to the clinical and economic 
impact of medicine treatments.
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Table III. Productivity costs of RA and AS, calculated through the HCA or the FCA: 
number of studies reporting costs (n), mean costs, and inter-quartile range (IQR) associated 
with the mean costs (€ per patient per year).  
 
 n Mean  0.25 – 0.75 IQR    
Rheumatoid arthritis (n=16)   
Short-term absence / sick leave 6 2770 855-2378
Work disability / early retirement (HCA) 4 6467 4195-8999
Total productivity costs (HCA) 14 8452 4144-11566
Work disability / early retirement (FCA) 2 865 412-1067
Total productivity costs (FCA) 4 1441 702-1307
   
Ankylosing spondylitis (n=6)   
Short-term absence / sick leave 4 913 388-1079
Work disability / early retirement (HCA) 4 5657 4777-7271
Total productivity costs (HCA) 5 6278 5111-7725
Work disability / early retirement (FCA) 2 884 706-1062
Total productivity costs (FCA) 2 2271 1572-2970
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Key messages
1. Productivity costs constitute the larg-
est part of the total cost-off-illness of 
RA and AS.
2. Overall mean patients costs of RA 
(€14,906 per year) were above that 
of AS (€9,374 per year).
3. The lifetime costs of AS, compared 
to RA, may however be equal or 
higher due to the earlier onset of AS. 
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